



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/59	A1	(11) International Publication Number: WO 96/40153 (43) International Publication Date: 19 December 1996 (19.12.96)
<p>(21) International Application Number: PCT/US96/09221</p> <p>(22) International Filing Date: 6 June 1996 (06.06.96)</p> <p>(30) Priority Data: 08/486,387 7 June 1995 (07.06.95) US</p> <p>(71) Applicant: BONE CARE INTERNATIONAL, INC. [US/US]; 313 West Beltline Highway, Madison, WI 53713 (US).</p> <p>(72) Inventors: KNUTSON, Joyce, C.; 24 North Prospect Street, Madison, WI 53705 (US). BISHOP, Charles, W.; 5 La Pointe Terrace, Madison, WI 53719 (US).</p> <p>(74) Agents: WELCH, Teresa, J. et al.; Stroud, Stroud, Willink, Thompson & Howard, Suite 300, 25 West Main Street, P.O. Box 2236, Madison, WI 53701-2236 (US).</p>		<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
(54) Title: USE OF VITAMIN D ₄ DERIVATIVES FOR TREATING CANCER		
<p>(57) Abstract</p> <p>Novel 1α-hydroxy vitamin D₄ and novel analogues, and preferably 1,24 dihydroxy vitamin D₄, which are useful as active compounds of pharmaceutical compositions for the treatment of disorders of calcium metabolism and breast and colon cancers.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

USE OF VITAMIN D₄ DERIVATIVES FOR TREATING CANCER

TECHNICAL FIELD

This invention relates to biologically active vitamin D₄ compounds.
5 More specifically, this invention relates to novel 1 α -hydroxy vitamin D₄ and novel intermediates used in its synthesis, novel 1,25 dihydroxy vitamin D₄, and novel 1,24 dihydroxy vitamin D₄.

This invention also relates to a pharmaceutical composition which includes a pharmaceutically effective amount of the novel 1 α -hydroxy
10 vitamin D₄ compounds, and to a method of controlling abnormal calcium metabolism by administering a pharmaceutically effective amount of the novel compounds.

BACKGROUND

Vitamin D is known to be important in the regulation of calcium
15 metabolism in animals and man. See, Harrison's Principals of Internal Medicine: Part Eleven, "Disorders of Bone and Mineral Metabolism, Chapter 335," E. Braunwald, et al., (eds.), McGraw-Hill, New York, 1987, pp. 1860-1865. The two most commonly known, useful forms of vitamin D are vitamin D₃ and vitamin D₂. Vitamin D₃ is synthesized
20 endogenously in the skin of animals and man, whereas vitamin D₂ is the form of vitamin D supplied by plants. Vitamin D₂ differs from vitamin D₃ in that it contains a double bond between C22 and C23 and further contains a C24-methyl group. In man and rats, vitamin D₃ and vitamin D₂ have equivalent biopotency.

25 Vitamin D₄, also known as irradiated 22,23-dihydro-ergosterol or 22,23-dihydro vitamin D₂ or 22,23-dihydroergocalciferol, differs from vitamin D₃ in that it contains a C24 methyl group. Vitamin D₄ was first

-2-

described in 1936. See, Grab, W., Z. Physiol. Chem., 243:63 (1936); McDonald, F.G., J. Biol. Chem., 114:IVX (1936). See also, Windaus, A. and Trautmann, G., Z. Physiol. Chem., 247:185-188 (1937). These references report some disagreement as to the level of biological activity of the vitamin suggesting that in the rat, vitamin D₄ is one-third or three-fourths as active as vitamin D₃ and in the chick, either one-tenth or one-fifth as active as vitamin D₃.

A more definitive study of the biological activity of vitamin D₄ was made by DeLuca, et al., in 1968. DeLuca, et al., Arch. Biochem. Biophys., 124:122-128 (1968). There, the authors confirmed that vitamin D₄ was less active than vitamin D₃. DeLuca, et al., report that, in their hands, vitamin D₄ is two-thirds as active as vitamin D₃ or vitamin D₂ in the rat, and one-fifth as active as vitamin D₃ in the chick.

DeLuca, et al., make reference to the fact that "[t]he synthesis of vitamin D₄ has apparently been little used since it was first described by Windhaus and Trautmann," and comment, "[t]his is perhaps due to the fact that vitamin D₄ is only of academic interest."

To applicants' knowledge, vitamin D₄ has remained "only of academic interest" as applicants are unaware of any further study of vitamin D₄ since that reported by DeLuca, et. al. In fact, The Merck Index states with respect to vitamin D₄, "Its biological activity seems doubtful." Merck Index, S. Budavari (ed.), 11th ed., Merck & Co., Rahway, N.J., (1989) pp. 1579, #9930.

Since DeLuca, et. al., discovered the active form of vitamin D₃, 1,25-dihydroxy vitamin D₃, (U.S. Patent No. 3,697,559) and its synthetic precursor, 1 α -hydroxy vitamin D₃, (U.S. Patent 3,741,996), most interest has centered on developing therapeutic uses of these active vitamin D₃ metabolites. Unfortunately, while the vitamin D₃ metabolites held great promise as therapeutic agents, this promise has never been fully realized because of the extreme toxicity of these agents. For example, toxicity limits the efficacy of vitamin D₃, its active

-3-

forms and analogs, to prevent bone loss or restore lost bone. Many studies indicate that at dosages required for these agents to be effective in bone loss prevention or restoration, hypercalcemia and hypercalciuria are problems. It has been reported that 1α -hydroxy vitamin D_3 at a daily dose of $2\ \mu\text{g/day}$ (which has been shown in some studies to be effective in preventing loss of bone) causes toxicity in approximately 67% of patients. What is needed is a biopotent vitamin D metabolite of low toxicity, such that the drug is practical as a therapeutic agent.

SUMMARY OF THE INVENTION

The novel compounds of the invention, 1α -hydroxy vitamin D_4 , 1,25-dihydroxy vitamin D_4 and 1,24-dihydroxy vitamin D_4 , are bioactive forms of vitamin D_4 . The present inventors have discovered that these active forms of vitamin D_4 display much greater biopotency than would be predicted on the basis of the previously reported bioassays of vitamin D_4 . The present inventors have also discovered, that the bioactive novel compounds are less toxic than would be predicted on the basis of their biopotency. This combination of high activity with low toxicity makes the compounds of the invention useful as therapeutic agents in the treatment of disorders of calcium metabolism. The novel compounds of the invention are advantageously used as the active compounds of pharmaceutical compositions for diseases induced by abnormal metabolism of calcium.

In order to study the novel compounds of the invention, it was necessary to develop processes for their production. One α -hydroxy vitamin D_4 was made synthetically and in the course of that synthesis, novel intermediates were also produced. 1,25-dihydroxy vitamin D_4 and 1,24-dihydroxy vitamin D_4 are isolated as biological products of the metabolism of 1α -hydroxy vitamin D_4 .

Other advantages and a fuller appreciation of the specific adaptations, compositional variations, and physical and chemical

-4-

attributes of the present invention will be gained upon an examination of the following detailed description of the invention, taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

5 The present invention will hereinafter be described in conjunction with the appended drawings, wherein like designations refer to like elements throughout and in which:

Figure 1 illustrates preparative steps for the synthesis of vitamin D₄; and

10 Figure 2 illustrates preparative steps for the synthesis of 1 α -hydroxy vitamin D₄ starting with vitamin D₄.


DETAILED DESCRIPTION

15 The present invention provides synthetic 1 α -hydroxy vitamin D₂ (1 α -OH-D₄) compounds as well as tosylated and cyclic derivatives of vitamin D₄.

20 As used herein, the terms "biological activity" or "biologically active" are meant to refer to biochemical properties of compounds such as affecting metabolism, e.g., affecting serum calcium concentration, or binding to an appropriate receptor protein, e.g., binding to vitamin D receptor protein.

In one of its aspects, the invention encompasses the biologically active compounds of the general formula (I):

-5-



(I)

wherein R₁ is either H or OH, and R₂ is either H or OH, and salts, hydrates and solvates thereof. Preferred compounds among those of formula (I) are those in which R₁ and R₂ are both H; R₁ = OH and R₂ = H; and R₁ = OH.

In another aspect, the invention involves the preparation of compound of formula (II). Synthesis of 1 α -hydroxy vitamin D₄, i.e., compounds of formula (II) wherein R₁ and R₂ are H, is accomplished according to the schema presented in Figures 1 and 2. As seen in Figure 1, the synthesis uses ergosterol as the starting material. Ergosterol undergoes side chain saturation in a six-step process to yield 22,23-dihydroergosterol (VIII) using a procedure similar to that of Barton, et al., JCS Perkin I, 1976, 821-826. The 22,23-dihydroergosterol is then irradiated as described in Windaus, et al., Z. Physiol. Chem., 1937, 147:185, to yield vitamin D₄ [22,23-dihydroergocalciferol] (IX). As seen in Figure 2, vitamin D₄ is then hydroxylated in a four-step process to yield 1 α -hydroxy vitamin D₄ using a procedure similar to that described by Paaren, et al., J. Org. Chem., 1980, 45:3253.

Specifically, ergosterol is acetylated to form the 3β -acetate. This ergosterol acetate is subjected to hydroxyhalogenation at the 5,6 double bond to form the 6α -chloro- 5α -hydroxy derivative. This chlorohydrin is reduced and reacetylated to the 5α -hydroxy (i.e., 5α -ol) derivative. The 5α -ol is subjected to hydrogenation to saturate the side chain. The resulting 3β -acetoxysterol- 7α - 5α -ol is reduced to 22,23 dehydroergosterol acetate which is in turn reduced to yield 22,23 dehydroergosterol. The 22,23 dehydroergosterol is then irradiated to form vitamin D_4 . Vitamin D_4 is then tosylated to yield 3β -tosyl vitamin D_4 . The tosylate is displaced by solvolysis to yield the 6-methoxy-3,5-cyclovitamin D_4 . The cyclovitamin D_4 is subjected to allylic oxidation to form the 1α -hydroxy cyclovitamin derivative. The 1α -hydroxy cyclovitamin derivative is sequentially solvolyzed and subjected to a Diels-Alder-type reaction which removes the 5-methoxy group and separates the 1α -hydroxy vitamin D_4 (5,6-cis) from the 5,6 trans- 1α -hydroxy vitamin D_4 .

The 1,24 dihydroxy vitamin D_4 and 1,25 dihydroxy vitamin D_4 metabolites of 1α -hydroxy vitamin D_4 , are synthesized by incubating the 1α -hydroxy derivatives with human liver cells, culturing the cells, and recovering the 1,24 dihydroxy or 1,25 dihydroxy vitamin D_4 . Using vitamin D receptor protein binding tests, these metabolites are determined to be biologically active.

The compounds of formula (I) have been found to possess valuable pharmacological activity, namely, as controlling agents for calcium metabolism, especially serum calcium concentrations. Specifically, the compounds of formula (I) increase serum calcium concentrations in rats with vitamin D deficiency. It has also been found that the compounds of formula (I) have low toxicity, which enhances their pharmaceutical properties. Compounds of formula (I) have a toxicity, as measured by the LD_{50} test, which is similar to that of corresponding vitamin D_2 compounds and lower than that of

-7-

corresponding vitamin D₃ compounds. Thus, the compounds of the invention are applicable to various clinical and veterinary fields, and are particularly useful for the treatment of abnormal metabolism of calcium and phosphorus.

5 In a further aspect, the invention entails a method of controlling calcium metabolism, such as for treating abnormal calcium metabolism caused, e.g., by liver failure, renal failure, gastrointestinal failure, etc. The compounds of formula (I) can be used to treat prophylactically or therapeutically vitamin D deficiency diseases and related diseases, for
10 example, renal osteodystrophy, steatorrhea, anticonvulsant osteomalacia, hypophosphatemic vitamin D-resistant rickets, osteoporosis, including postmenopausal osteoporosis, senile osteoporosis, steroid-induced osteoporosis, and other disease states characteristic of loss of bone mass, pseudodeficiency (vitamin D-
15 dependent) rickets, nutritional and malabsorptive rickets, osteomalacia and osteopenias secondary to hypoparathyroidism, post-surgical hypoparathyroidism, idiopathic hypoparathyroidism, pseudohypoparathyroidism, and alcoholism.

 The compounds of formula (I), preferably those wherein R₁ or R₂
20 is OH, such as 1 α ,24 dihydroxy vitamin D₄, are of value for the treatment of hyperproliferative skin disorders such as psoriasis, eczema, lack of adequate skin firmness, dermal hydration and sebum secretion. Particularly preferred for use in the treatment of such skin disorders is the (R) stereoisomer of 1 α ,24-dihydroxy vitamin D₄, i.e., 1 α ,24(R)-
25 dihydroxy vitamin D₄, substantially free of its (S) form or in combination with a small quantity of the (S) form. Thus, the present invention provides a method of treating skin disorders by administering to a patient suffering therefrom, a therapeutically effective amount of a compound of formula (I), preferably a compound of formula (I) wherein
30 R₁ or R₂ is OH, such as 1 α ,24 dihydroxy vitamin D₄. More preferred is

-8-

the compound of formula (I) which is $1\alpha,24(R)$ -dihydroxy vitamin D_4 , substantially free of its (S) form.

5 The compounds of formula (I), preferably those wherein R_1 or R_2 is OH, such as $1\alpha,24$ dihydroxy vitamin D_4 , are additionally of value for inhibiting the hyperproliferative activity of malignant cells, i.e., cancer cells. In other words, the compounds of formula (I), particularly, e.g., $1\alpha,24$ dihydroxy vitamin D_4 , act as anti-proliferative agents when exposed to malignant cells. Particularly preferred for use as an anti-proliferative agent is the (R) stereoisomer of $1\alpha,24$ -dihydroxy vitamin D_4 ,
10 i.e., $1\alpha,24(R)$ -dihydroxy vitamin D_4 , substantially free of its (S) form or in combination with a small quantity of the (S) form. Thus, the present invention provides a method of treating malignant cells, e.g., human cancer cells, (i.e., inhibiting their hyperproliferative activity) with an effective amount of a compound of formula (I), preferably a compound
15 of formula (I) wherein R_1 or R_2 is OH, such as $1\alpha,24$ dihydroxy vitamin D_4 . More preferred is the compound of formula (I) which is $1\alpha,24(R)$ -dihydroxy vitamin D_4 , substantially free of its (S) form. The effective amount ranges from about $1 \mu\text{g}/\text{dose}$ to about $500 \mu\text{g}/\text{dose}$. Of particular value in the treatment of cancers, is the use of the
20 compounds of formula (I) for treatment of skin cancers, which use constitutes another aspect of the invention.

In particular, the compounds of formula (I) are valuable for the treatment of breast cancer and colon cancer. In another aspect, the invention is a method for treating the hyperproliferative cellular effects
25 of breast cancer and colon cancer by administering administering to a patient suffering therefrom, a therapeutically effective amount of a compound of formula (I), preferably a compound of formula (I) wherein R_1 or R_2 is OH, such as $1\alpha,24$ dihydroxy vitamin D_4 . More preferred is the compound of formula (I) which is $1\alpha,24(R)$ -dihydroxy vitamin D_4 ,
30 substantially free of its (S) form.

The compounds of formula (I) are additionally useful in the treatment of noncancerous skin disorders such as dermatitis, contact and ectopic.

5 The compounds of formula (I) are useful as active compounds in pharmaceutical compositions having reduced side effects and low toxicity as compared with the known analogs of active forms of vitamin D₃, when applied, for example, to diseases induced by abnormal metabolism of calcium. These pharmaceutical compositions constitute another aspect of the invention.

10 The pharmacologically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, e.g., mammals including humans. For example, the compounds of formula (I) can be employed in admixtures with conventional excipients, e.g.,
15 pharmaceutically acceptable carrier substances suitable for enteral (e.g., oral), parenteral, or topical application which do not deleteriously react with the active compounds.

 Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils
20 (e.g., corn oil, cottonseed oil, peanut oil, olive oil, coconut oil), fish liver oils, oily esters such as Polysorbate 80, polyethylene glycols, gelatine, carbohydrates (e.g., lactose, amylose or starch), magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose,
25 polyvinyl pyrrolidone, etc.

 The pharmaceutical preparations can be sterilized and, if desired, be mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or one or more other active
30 compounds, for example, vitamin D₃ or D₂ and their 1 α -hydroxylated metabolites, conjugated estrogens or their equivalents, anti-estrogens,

-10-

calcitonin, biphosphonates, calcium supplements, cobalamin, pertussis toxin and boron.

5 For parenteral application, particularly suitable are injectable, sterile solutions, preferably oily or aqueous solution, as well as suspensions, emulsions, or implants, including suppositories. Ampoules are convenient unit dosages.

10 For treatment of cancer, i.e., skin, breast and colon cancers, the parenteral dosage of the compounds of formula (I), preferably $1\alpha,24$ -dihydroxy vitamin D_4 , and more preferably $1\alpha,24(R)$ -dihydroxy vitamin D_4 , substantially free of its (S) form, is about $0.5 \mu\text{g}$ to about $50 \mu\text{g}$ per unit dosage.

15 For treatment of hyperproliferative skin disorders, such as psoriasis, the parenteral dosage of the compounds of formula (I), preferably $1\alpha,24$ -dihydroxy vitamin D_4 , and more preferably $1\alpha,24(R)$ -dihydroxy vitamin D_4 , substantially free of its (S) form, is about $0.5 \mu\text{g}$ to about $50 \mu\text{g}$ per unit dosage.

20 For enteral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, lozenges, powders, or capsules. A syrup, elixir, or the like can be used if a sweetened vehicle is desired.

25 Sustained or directed release compositions can also be formulated, e.g., liposomes or those in which the active compound is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc.

25 For topical application, suitable nonsprayable viscous, semi-solid or solid forms can be employed which include a carrier compatible with topical application and having a dynamic viscosity preferably greater than water. Suitable formulations include, but are not limited to, solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, aerosols, transdermal patches, etc., which are, if
30 desired, sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, demulsifiers, wetting agents, etc.

-11-

Topical preparations of the compound in accordance with the present invention useful for the treatment of skin disorders may also include epithelialization-inducing agents such as retinoids (e.g., vitamin A), chromanols such as vitamin E, β -agonists such as isoproterenol or cyclic adenosine monophosphate (cAMP), anti-inflammatory agents such as corticosteroids (e.g., hydrocortisone or its acetate, or dexamethasone) and keratoplastic agents such as coal tar or anthralin. Effective amounts of such agents are, for example, vitamin A about 0.003 to about 3% by weight of the composition, vitamin E about 0.1 to about 10%; isoproterenol about 0.1 to about 2%; cAMP about 0.1 to about 1%; hydrocortisone about 0.25% to about 5%; coal tar about 0.2 to about 20%; and anthralin about 0.05 to about 2%.

For topical treatment of skin disorders, the dosage of the compounds of formula (I), preferably $1\alpha,24$ -dihydroxy vitamin D_4 , and more preferably $1\alpha,24(R)$ -dihydroxy vitamin D_4 , substantially free of its (S) form, in a locally applied composition is about 1 μg to about 100 $\mu\text{g}/\text{gram}$ of composition.

For treatment of cancer, i.e., skin, breast and colon cancers, the dosage of the compounds of formula (I), preferably $1\alpha,24$ -dihydroxy vitamin D_4 , and more preferably $1\alpha,24(R)$ -dihydroxy vitamin D_4 , substantially free of its (S) form, in a locally applied composition is about 1 μg to about 100 $\mu\text{g}/\text{gram}$ of composition.

For treatment of hyperproliferative skin disorders, such as psoriasis, the dosage of the compounds of formula (I), preferably $1\alpha,24$ -dihydroxy vitamin D_4 , and more preferably $1\alpha,24(R)$ -dihydroxy vitamin D_4 , substantially free of its (S) form, in a topical composition is about 1 μg to about 100 $\mu\text{g}/\text{gram}$ of composition.

For rectal administration, compounds are formed into a pharmaceutical composition containing a suppository base such as cacao oil or other triglycerides. To prolong storage life, the composition

-12-

advantageously includes an antioxidant such ascorbic acid, butylated hydroxyanisole or hydroquinone.

Oral administration of the pharmaceutical compositions of the present invention is preferred. Generally, the compounds of this invention are dispensed by unit dosage form comprising about 0.5 μg to about 25 μg in a pharmaceutically acceptable carrier per unit dosage. The dosage of the compounds according to this invention generally is about 0.01 to about 0.5 $\mu\text{g}/\text{kg}/\text{day}$, preferably about 0.04 to about 0.3 $\mu\text{g}/\text{kg}/\text{day}$.

It will be appreciated that the actual preferred amounts of active compound in a specific case will vary according to the efficacy of the specific compound employed, the particular compositions formulated, the mode of application, and the particular situs and organism being treated. For example, the specific dose for a particular patient depends on the age, body weight, general state of health, sex, on the diet, on the timing and mode of administration, on the rate of excretion, and on medicaments used in combination and the severity of the particular disorder to which the therapy is applied. Dosages for a given host can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the subject compounds and of a known agent, such as by means of an appropriate conventional pharmacological protocol.

In a still further aspect, the compounds of the present invention can also be advantageously used in veterinary compositions, for example, feed compositions for domestic animals to treat or prevent hypocalcemia. Generally, the compounds of the present invention are dispensed in animal feed such that normal consumption of such feed provides the animal about 0.01 to about 0.5 $\mu\text{g}/\text{kg}/\text{day}$.

The following examples are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. In the following examples, all temperatures are set forth

-13-

in degrees Celsius; unless otherwise indicated, all parts and percentages are by weight. Proton nuclear magnetic (^1H NMR) spectra were recorded with an IBM Sy-200(200 MHz) and a Bruker Am-400(400 MHz) with aspect 3000 Computer in CDCl_3 solutions with CHCl_3 as an internal standard. Infrared spectra were recorded with a Fourier transform (FTIR) using samples as potassium bromide (KBr) pellets or as liquids. Mass spectra were recorded with a Finnigan MAT-90 mass spectrometer at 20 eV/Cl. Melting points are determined on a Hoover-Thomas (capillary) Uni-Melt and a Fisher-Johns melting point apparatus (cover-slip type).

Example 1: Synthesis of 1α -hydroxy vitamin D_4

Ergosterol (II) was converted to ergosterol acetate (III) by dissolving 100 g (0.25 mol) ergosterol in 600 ml of anhydrous pyridine and 68 ml (0.7 mol) acetic anhydride. The solution was stirred overnight at room temperature after which time the solution was cooled by adding 1.2 L ice, causing a precipitate to form. The precipitate was washed five times with 400 ml portions of water, then once with 400 ml of CH_3CN . The resulting product was air dried to yield 79 g (71%) of ergosterol acetate as a white crystalline solid and had the following characteristics: melting point (m.p.): $169-171^\circ\text{C}$; ^1H NMR: (400 MHz, CDCl_3), δ ppm 2.05 (3H, s, $3\beta\text{-CH}_3\text{CO}$), 4.65-4.75 (1H, m, $3\alpha\text{-H}$) 5.15-5.25 (2H, m, 22-H and 23-H), 5.4 (1H, d, 6-H), 5.6 (1H, d, 7-H); FTIR [KBr]: 1734 cm^{-1} (C=O stretching) 968 cm^{-1} (C-H bending).

Ergosterol acetate (III) (26 gm, 0.062 M) was dissolved in 2.5 L of freshly distilled deoxygenated toluene. To this solution 9 ml (0.111 mol) chromyl chloride dissolved in 240 ml dry CH_2Cl_2 was added under nitrogen at -78°C over a thirty minute period. The reaction system was stirred at -78°C for an additional fifteen minutes, and then 62 ml of a saturated solution of sodium borohydride in ethanol was added in one portion. After stirring at -78°C for an additional fifteen

-14-

minutes, the reaction solution was poured into a two phase system of 3N hydrochloric acid (3L) and benzene (3L). The organic layer was separated, then washed with water (2L), twice with a brine solution (2 x 1L) and then dried with anhydrous MgSO_4 . The dried solution was filtered and concentrated in vacuo. The crude crystalline product was then treated with CH_3CN (280ml) and filtration of the thus formed slurry yielded 12.5 g (41%) of white crystalline 3β -Acetoxy- 6α -chloroergosta-7,22-dien- 5α -ol (IV) and had the following characteristics: m.p.: 190-192°C; ^1H NMR: (400 MHz, CDCl_3), δ ppm 2.05 (3H, s, 3β -OAc), 4.65 (1H, d, 6β -H), 5.1 (1H, s, 7-H), 5.1-5.3 (2H, m, 22-H and 23-H); FTIR [KBr]: 1732 cm^{-1} (C=O stretching), 968 cm^{-1} (C-H bending), 3437 cm^{-1} (O-H stretching).

The 3β -Acetoxy 6α -chloroergosta-7,22-dien- 5α -ol (IV) (21.4 g, 0.044 mol) in dry THF (900 ml) was added slowly to a stirred suspension of lithium aluminium hydride (2.66 g, 0.07 mol) in dry THF (750 ml) at room temperature under nitrogen. The mixture was refluxed for three hours and cooled to 0°C. Excess hydride was decomposed with saturated Na_2SO_4 solution. Filtration through anhydrous Na_2SO_4 and evaporation of the filtrate gave a solid, which was treated directly with acetic anhydride (110 ml) and dry pyridine (220 ml) at 0°C. Removal of solvent under reduced pressure yielded the acetate (12.75 g, 61%), 3β -Acetoxyergosta-7,22-dien- 5α -ol (V) and had the following characteristics: m.p.: 229-232°C; FTIR [KBr] 1736 cm^{-1} (C=O stretching), 3460 cm^{-1} (O-H stretching), 972 cm^{-1} (C-H bending).

3β -Acetoxyergosta-7,22-dien- 5α -ol (V) (2.5 g, 0.0055 mol) was shaken for sixteen hours with freshly prepared PtO_2 (0.5 g) in ethyl acetate (820 ml) under H_2 gas (15 psi). The catalyst was removed by filtration and evaporation of the filtrate gave the crude acetate which was dissolved in CH_2Cl_2 and chromatographed on silica gel. Elution with CH_2Cl_2 gave substantially pure 3β -Acetoxyergost-7-en- 5α -ol (VI) (2.15 g, 85%) as a white crystalline material and had the following

-15-

characteristics: m.p.: 228-232°C; ¹H NMR: (400 MHz, CDCl₃), δppm 2.05 (3H, s, 3β-OAc), 5.05-5.20 (2H, m, 3α-H and 7-H); FTIR [KBr]: 1736 cm⁻¹ (C=O stretching), 3462 cm⁻¹ (O-H stretching).

5 Redistilled thionyl chloride (9.7 ml) in dry pyridine (170 ml) was added to compound 3β-Acetoxyergost-7-en-5α-ol (VI) (12.0 g, 0.0262 mol) in dry pyridine (800 ml) at 0°C under nitrogen. After 2.5 hours, the solution was diluted with ice cold H₂O (1.5 L) and extracted with two portions of ether (2.5 L + 1.5 L). The combined ether extracts were washed with a NaHCO₃ solution (1.0 L x 2), then 10 1N HCl (1.5 L x 2) and then water (1 L). The ether solution was dried with MgSO₄, and after filtration, evaporated under reduced pressure to yield a crude product which was converted to a slurry with CH₃CN (100 ml). The product was collected by filtration and recrystallized from CH₃CN to yield 4.5 g. (39%) of a white crystalline 22,23-15 dihydroergosteryl acetate (VII) and had the following characteristics: m.p.: 144-147°C; ¹H NMR: (400 MHz, CDCl₃), δppm 2.05 (3H, s, 3β-OAc), 4.65-4.75 (1H, m, 3α-H), 5.4 (1H, d, 6-H), 5.6 (1H, d, 7-H); FTIR [KBr]: 1734 cm⁻¹ (C=O stretching).

20 22,23-dihydroergosteryl acetate (VII) (4.8 g, 0.011 mol) was added at once to a stirred suspension of lithium aluminium hydride (2.5 g, 0.066 mol) in dry ether (1.1 L) at room temperature. The mixture was stirred for two hours at room temperature. 5N NaOH was added to destroy excess lithium aluminium hydride and H₂O (500 ml) was then added. The aqueous solution was then extracted with four 25 250 ml portions of ether. The combined ether extracts and combined organic layer were washed with brine solution (1 L), then dried with Na₂SO₄. Evaporation of ether under reduced pressure gave the compound, 22,23-dihydroergosterol, (VIII) (4.1 g, 94%) as a white crystalline material and had the following characteristics: m.p.: 147-30 150°C; ¹H NMR: (400 MHz, CDCl₃), δppm 3.6-3.7 (1H, m, 3α-H), 5.4 (1H, d, 6H), 5.6 (1H, d, 7-H); FTIR [KBr]: 3400 cm⁻¹ (O-H stretching).

-16-

22,23-dihydroergosterol (VIII) (2.0 g, 5.0 mmol) was dissolved in a solution of diethyl ether and benzene (4:1, 600 ml) and irradiated (Hannovia immersion lamp, 450 watts) with stirring under argon in a water-cooled quartz vessel for three hours. The solution was concentrated in vacuo to yield a gummy solid, which was redissolved in 100 ml. of ethanol and heated at reflux under argon for eight hours. Then, the solution was concentrated in vacuo and the residue was adsorbed on a silica gel column and eluted with 30% ethyl acetate in hexane to afford vitamin D₄ (22,23-dihydroergocalciferol) (IX) with a yield of 1.2 g. (60%) and with the following characteristics: ¹H NMR: (400 MHz, CDCl₃), δppm 0.55 (3H, s, 18-H₃) 0.78 (6H, dd, 26-H₃ and 27-H₃) 0.87 (3H, d, 21-H₃) 0.93 (3H, d, 28-H₃) 3.94 (1H, m, 3-H) 4.82 (1H, m (sharp), 19-H), 5.04 (1H, m (sharp), 19-H), 6.04 (1H, d, 7-H) 6.24 (1H, d, 6-H).

To a stirred solution of vitamin D₄ (IX) (3.0 g, 7.5 mmol) in 10 ml of dry pyridine was added freshly recrystallized p-toluenesulfonyl chloride (3.6 g, 19 mmol) at 0°C. The reaction mixture was stirred at 5°C for 24 hours, and was then quenched by pouring the mixture over ice and saturated NaHCO₃ (100 ml) with stirring. The aqueous suspension was extracted with CH₂Cl₂ (3 x 300 ml). The combined organic extracts were washed with 10% HCl (3 x 200 ml), saturated NaHCO₃ (3 x 200 ml) and saturated NaCl (2 x 200 ml), dried over MgSO₄ and concentrated in vacuo to yield 3.5 g. (84%) of the novel intermediate compound vitamin D₄ tosylate (X) and had the following characteristics: ¹H NMR (400 MHz, CDCl₃), δppm 0.54 (3H, s, 18-H₃) 0.78 (6H, dd, 26-H₃ and 27-H₃) 0.87 (3H, d, 21-H₃), 0.96 (3H, d, 28-H₃) 2.45 (3H, s, CH₃ (tosylate)) 4.68 (3H, m, 3-H) 4.82 (1H, m (sharp), 19-H) 5.04 (1H, m (sharp), 19-H), 5.95 (1H, d 7-H), 6.09 (1H, d, 6-H) 7.34 and 7.79 (4H, d, aromatic).

To a stirred suspension of NaHCO₃ (17.0 g, 202 mmol) in methanol (200 ml) a solution of vitamin D₄ tosylate (X) (3.5 g,

-17-

6.3 mmol) in dry CH_2Cl_2 (10 ml) was added dropwise. The reaction mixture was refluxed overnight under argon, and then cooled to room temperature and concentrated in vacuo to about 50 ml. The reaction concentrate was diluted with ether (600 ml), washed with water (3 x 300 ml), dried over MgSO_4 and concentrated in vacuo. The residue was passed through a silica gel column and eluted with 10% ethyl acetate in hexane to afford the novel intermediate compound 3,5-cyclovitamin D_4 (XI) (heavy oil) with a yield of 1.5 g. (58%) and had the following characteristics: ^1H NMR (400 MHz, CDCl_3), δ ppm 0.56 (3H, s, 18- H_3) 0.78 (6H, dd, 26- H_3 and 27- H_3), 0.87 (3H, d, 21- H_3), 0.94 (3H, d, 28- H_3), 3.28 (3H, s, OCH_3) 4.2 (1H, d, 6-H), 4.91 (1H, m (sharp), 19-H), 4.98 (1H, d 7-H), 5.08 (1H, m (sharp), 19-H).

Anhydrous tert-butyl hydroperoxide in toluene (3M) (2.6 ml, 7.8 mmol) was added to a stirred suspension of selenium dioxide (0.22 g, 2 mmol) in dry CH_2Cl_2 (150 ml) in a three necked flask. The mixture was stirred for three hours under argon. Pyridine (0.3 ml, 3.7 mmol) was then added, and cyclovitamin D_4 (XI) (1.5 g, 3.6 mmol) was then introduced as a solution in CH_2Cl_2 (50 ml). After stirring for thirty minutes, 10% aqueous NaOH solution (200 ml) was added. The reaction mixture was then diluted with ether (500 ml) and the phases were separated. The organic phase was washed with 10% NaOH (3 x 200 ml), water (2 x 200 ml) and saturated NaCl solution (2 x 200 ml), dried over MgSO_4 and concentrated in vacuo. The residue was absorbed on a silica gel column and eluted with 30% ethyl acetate in hexane to afford 0.45 g. (29%) of the novel intermediate compound 1 α -hydroxy 3,5-cyclovitamin D_4 (XII) (oil) and had the following characteristics: ^1H NMR (400 MHz, CDCl_3), δ ppm 0.54 (3H, s, 18- H_3) 0.78 (6H, dd, 26- H_3 and 27- H_3) 0.86 (3H, d, 21- H_3) 0.95 (3H, d, 28- H_3) 3.26 (3H, s, OCH_3) 4.2 (1H, d, 6-H), 4.22 (1H, m, 1-H), 4.95 (1H, d 7-H), 5.18 (1H, d, 19-H) 5.25 (1H, d, 19-H).

-18-

A solution of 1 α -hydroxy 3,5-cyclovitamin D₄ (XII) (0.45 g, 1.05 mmol) in a solution of dimethyl sulfoxide (4.5 ml) and glacial acetic acid (3.6 ml) was heated to 50°C under argon for one hour. The reaction mixture was then poured over ice and saturated NaHCO₃ solution (100 ml), and extracted with ether (3 x 200 ml). The combined ether extracts were washed with saturated NaHCO₃ solution (3 x 200ml), water (3 x 200 ml) and saturated NaCl solution (3 x 200 ml), dried over MgSO₄, concentrated in vacuo to give a mixture containing 5,6-cis and 5,6-trans 1 α -hydroxy vitamin D₄ (about 4:1 by ¹H NMR) with a yield of 0.4g, (92%). The mixture of 5,6-cis and 5,6-trans 1 α -hydroxy vitamin D₄ (0.4 g, 0.97 mmol) was dissolved in ethyl acetate (25 ml) and treated with freshly recrystallized maleic anhydride (0.08 g, 0.8 mmol). This reaction mixture was heated to 35°C under argon for 24 hours. After evaporation of the solvent in vacuo, the crude mixture was chromatographed over a silica gel column using ethyl acetate and hexane (1:1) as eluent, to afford the novel active form of vitamin D₄, 5,6-cis 1 α -hydroxy vitamin D₄ (XIII) with a yield of 90 mg (23%) and had the following characteristics: m.p.: 128-130°C; IR ν_{\max} (Neat): 3400 cm⁻¹ (OH stretching); ¹H NMR (400 MHz, CDCl₃), δ ppm 0.55 (3H, s, 18-H) 0.79 (6H, dd, 26-H₃ and 27-H₃) 0.87 (3H, d, 21-H₃) 0.94 (3H, d, 28-H₃), 4.24 (1H, m, 3-H), 4.44 (1H, m, 1-H), 5.02 (1H, m (sharp), 19-H), 5.34 (1H, m (sharp), 19-H), 6.02 (1H, d 7-H), 6.4 (1H, d, 6-H); Mass spectrum [CI] m/e (relative intensity): 415 (M+1, 41%) 397, (M+1-OH 100%), 379 (27%), 135 (22%).

Example 2: Biological testing of 1 α -hydroxy vitamin D₄

Male weanling rats (Holtzman strain, Holtzman Company, Madison, Wisconsin) were fed a vitamin D deficient diet containing adequate calcium (0.47%) and phosphorus (0.3%). Within three to four weeks, this diet induces an extreme vitamin D deficiency characterized by low serum calcium and poor growth. After four weeks on this diet,

-19-

the rats had serum calcium values less than 7 mg/dl. The rats were then separated into four groups and orally administered either 1 α -hydroxy vitamin D₄ in a vehicle such as coconut oil or the vehicle (control) for each of 14 days. Twenty-four hours after the last dose, the rats were killed and the blood calcium measured by a standard laboratory technique. The results of these determinations are shown in Table 1.

TABLE 1

Increase in Serum Calcium Concentration

10	<u>Compound</u>	<u>Dose</u> <u>(μg/kg/day)</u>	<u>Number</u> <u>of Rats</u>	<u>Serum calcium</u> <u>concentration (mg/dl)</u> <u>\pm Standard Deviation</u>
	Control	-	10	6.1 \pm 0.48
	1 α -OH-D ₄	0.042	8	7.1 \pm 0.80
	1 α -OH-D ₄	0.250	7	11.6 \pm 0.45
	1 α -OH-D ₄	1.500	9	12.7 \pm 0.37

15 The data of Table 1 indicate that 1 α -hydroxy vitamin D₄ is effective at increasing serum calcium in the vitamin D deficient rat and that the response appears to be dose dependent. Surprisingly, the level of the response appears to compare favorably to that reported by Wientroub, et. al., for 1,25 dihydroxy vitamin D₃ administered to vitamin D deficient rats under experimental conditions similar to those described above.

20 See, Wientroub, S., Price, P.A., Reddi, A.H., "The Dichotomy in the Effects of 1,25 dihydroxy vitamin D₃ and 24,25 dihydroxy vitamin D₃ on Bone Gamma-Carboxyglutamic Acid-Containing Protein in Serum and Bone in vitamin D-Deficient Rats," Calcif. Tissue Int. (1987)

25 40:166-172.

-20-

Example 3: Toxicity tests

The acute oral toxicity of 1α -OH- D_4 in rats was assessed by determining the mean lethal dose (LD_{50}) using a well-known method. Rats were fed a standard laboratory diet for 8-10 weeks. Five animals of each sex were administered one oral dose of 1α -OH- D_4 . The animals were observed for 14 days, and the number of deaths noted. The LD_{50} value was determined to be about 1.0 mg/kg in males and 3.0 mg/kg in females.

For comparison, the LD_{50} value for 1α -hydroxy vitamin D_2 under the same conditions was found by applicant's to be 1.7 and 1.8 mg/kg. in male and female rats, respectively. The toxicity of 1α -hydroxy vitamin D_2 has previously been reported as less than 1α -hydroxy vitamin D_3 . Sjoden, G., Smith, C., Lindgren, U., and DeLuca, H.F., Proc. Soc. Experimental Biol. Med., 178:432-436 (1985).

Example 4: Generation and Isolation of 1,25-dihydroxy vitamin D_4

The 1α -hydroxy vitamin D_4 of the present invention is incubated with cultured human liver cells which metabolize the compound to several products including the metabolite 1,25 dihydroxy vitamin D_4 . The 1,25 metabolite is isolated and purified by high pressure liquid chromatography and identified by gas-chromatography-mass spectrometry. Binding studies demonstrate that the 1,25 dihydroxy vitamin D_4 has good binding affinity for the mammalian vitamin D receptor protein indicating it is biologically active. The procedures used are similar to that described by Strugnell, et. al., Biochem. Pharm. Vol. 40:333-341 (1990).

Example 5: Generation and isolation of 1,24-dihydroxy vitamin D_4

Generation and isolation of 1,24 dihydroxy vitamin D_4 is accomplished as described in Example 4, above. The 1α -hydroxy

-21-

vitamin D₄ of the present invention is incubated with cultured human liver cells which metabolize the compound to several products including the metabolite 1,24 dihydroxy vitamin D₄. The 1,24 metabolite is isolated and purified using high pressure liquid chromatography and identified by gas-chromatography-mass spectrometry. Binding studies with the new metabolite demonstrate that the metabolite has good binding affinity for the mammalian vitamin D receptor protein which indicates the drug is biologically active.

Example 6: Hypercalcemia testing

Female rats are fed a commercial diet containing 0.8% calcium (0.8%) and phosphorus (0.6%). The rats are divided into four groups and each group is orally administered daily either 1 α -OH D₄ in a vehicle such as coconut oil or the vehicle (control) alone for 13 weeks. Twenty-four hours after the last dose, the rats are killed and their serum calcium determined by a standard method.

This procedure demonstrates that the serum calcium concentration is unaffected or only slightly elevated at doses 1 α -OH-D₄ up to 2.5 μ g/kg/day.

Example 7: Further biological testing

Male weanling rats are fed a diet deficient in vitamin D and with low calcium (0.02%). After a period of four weeks has elapsed, the rats are divided into four groups and intravenously administered either 1 α -OH D₄ in a vehicle such as ethanol or the vehicle (control) alone. Sixteen hours after administration, the rats are killed and the intestinal calcium transport measured by using everted duodenal sacs, following the method of Martin and DeLuca, Am. J. Physiol. 216:1352-1359.

Following this procedure demonstrates stimulation of intestinal calcium transport in a dose dependent manner.

Example 8:

5 A clinical study is conducted with postmenopausal osteoporotic outpatients having ages between 55 and 75 years. The study involves up to 120 patients randomly divided into three treatment groups, and continues for 12 to 24 months. Two of the treatment groups receive constant dosages of 1α -vitamin D_4 (u.i.d.; two different dose levels above $3.0 \mu\text{g/day}$) and the other group receives a matching placebo. All patients maintain a normal intake of dietary calcium (500 to 800 mg/day) and refrain from using calcium supplements. Efficacy is evaluated by pre- and post-treatment comparisons of the patient groups with regard to (a) total body, radial, femoral and/or spinal bone mineral density as determined by x-ray absorptiometry (DEXA), (b) bone biopsies of the iliac crest, and (c) determinations of serum osteocalcin. Safety is evaluated by comparisons of urinary hydroxyproline excretion, serum and urine calcium levels, creatinine clearance, blood urea nitrogen, and other routine determinations.

10 This study demonstrates that patients treated with 1α -vitamin D_4 exhibit significantly higher total body, radial, femoral and/or spinal bone densities relative to patients treated with placebo. The treated patients also exhibit significant elevations in serum osteocalcin. Bone biopsies from the treated patients show that 1α -vitamin D_4 stimulates normal bone formation. The monitored safety parameters confirm an insignificant incidence of hypercalcemia or hypercalciuria, or any other metabolic disturbance with 1α -vitamin D_4 therapy.

25 **Example 9:**

30 A clinical study is conducted with healthy postmenopausal women having ages between 55 and 60 years. The study involves up to 80 patients randomly divided into two treatment groups, and continues for 12 to 24 months. One treatment group receives a constant dosage of 1α -vitamin D_4 (u.i.d.; a dose level above $3.0 \mu\text{g/day}$) and the other

-23-

receives a matching placebo. The study is conducted as indicated in Example 2 above.

5 This study demonstrates that patients treated with 1α -vitamin D_4 exhibit reduced losses in total body, radial, femoral and/or spinal bone densities relative to baseline values. In contrast, patients treated with placebo show significant losses in these parameters relative to baseline values. The monitored safety parameters confirm the safety of long-term 1α -vitamin D_4 administration at this dose level.

Example 10:

10 A twelve-month double-blind placebo-controlled clinical trial is conducted with thirty men and/or women with renal disease who are undergoing chronic hemodialysis. All patients enter an eight-week control period during which time they receive a maintenance dose of vitamin D_3 (400 IU/day). After this control period, the patients are
15 randomized into two treatment groups: one group receives a constant dosage of 1α -vitamin D_4 (u.i.d.; a dosage greater than $3.0 \mu\text{g/day}$) and the other group receives a matching placebo. Both treatment groups receive a maintenance dosage of vitamin D_3 , maintain a normal intake of dietary calcium, and refrain from using calcium supplements.
20 Efficacy is evaluated by pre- and post-treatment comparisons of the two patient groups with regard to (a) direct measurements of intestinal calcium absorption, (b) total body, radial, femoral and/or spinal bone mineral density, and (c) determinations of serum calcium and osteocalcin. Safety is evaluated by regular monitoring of serum calcium.

25 Analysis of the clinical data shows that 1α -vitamin D_4 significantly increases serum osteocalcin levels and intestinal calcium absorption, as determined by measurements using a single or double-isotope technique. Patients treated with this compound show normalized serum calcium levels, stable values for total body, radial, femoral and/or spinal bone
30 densities relative to baseline values. In contrast, patients treated with

-24-

placebo show frequent hypocalcemia, significant reductions in total body, radial, femoral and/or spinal bone density. An insignificant incidence of hypercalcemia is observed in the treated group.

Example 11: Medicament preparations

5 A topical cream is prepared by dissolving 1.0 mg of
1 α ,24-dihydroxy vitamin D₄ in 1 g of almond oil. To this solution is
added 40 gm of mineral oil and 20 gm of self-emulsifying beeswax. The
mixture is heated to liquify. After the addition of 40 ml hot water, the
mixture is mixed well. The resulting cream contains approximately
10 10 μ g of 1 α ,24-dihydroxy vitamin D₄ per gram of cream.

Example 12:

 An ointment is prepared by dissolving 1.0 mg of 1 α ,24-dihydroxy
vitamin D₄ in 30 g of almond oil. To this solution is added 70 gm of
white soft paraffin which had been warmed just enough to be liquified.
15 The ointment is mixed well and allowed to cool. This ointment contains
approximately 10 μ g 1 α ,24-dihydroxy vitamin D₄ per gram of ointment.

Example 13:

 To the ointment of Example 12 is added with thorough mixing
0.5 g of adenosine and 2.0 g of papaverine base, both dissolved in a
20 minimum quantity of dimethyl sulfoxide. The additional ingredients are
present to the extent of about 0.5 wt % (adenosine) and 2 wt %
(papaverine base).

Example 14:

 To the ointment of Example 12 is added with thorough mixing
25 10,000 U of Vitamin A dissolved in a minimum quantity of vegetable oil.

-25-

The resultant ointment contains about 100 U Vitamin A per gram of the ointment.

Example 15:

5 A dermatological lotion is prepared by dissolving 1.0 mg of 1 α ,24-dihydroxy vitamin D₄ in 100 g of dry propylene glycol. The lotion is stored in a refrigerator in a brown bottle and contains about 10 μ g of 1 α ,24-dihydroxy vitamin D₄ per gram of lotion.

Example 16:

10 In 1 g of almond oil is dissolved 0.2 mg of 1 α ,24-dihydroxy vitamin D₄. To the solution is added 40 g of mineral oil and 20 g of self-emulsifying beeswax, followed by 40 ml of hot water. The mixture is mixed well to produce a cosmetic cream containing about 2.0 μ g of 1 α ,24-dihydroxy vitamin D₄ per gram of cream.

Example 17:

15 To a cosmetic cream prepared according to Example 16 is added 100 mg adenosine. The cream is mixed well and contains about 0.1 wt % adenosine.

Example 18:

20 An ointment is prepared by dissolving 100 μ g of 1 α ,24-dihydroxy vitamin D₄ in 30 g of almond oil. To the solution so produced is added 70 g white soft paraffin which had been warmed just enough to be liquified. The ointment is mixed well and allowed to cool. The ointment so produced contains about 1.0 μ g of 1 α ,24-dihydroxy vitamin D₄ per gram of ointment.

Example 19:

To the cosmetic ointment of Example 18 is added with thorough mixing 200 U/g Vitamin A dissolved in a minimum amount of vegetable oil.

5 Example 20:

A cosmetic lotion is prepared by dissolving 300 μg of 1 α ,24-dihydroxy vitamin D₄ in 100 g of dry propylene glycol. The lotion is stored in a refrigerator in a brown bottle and contains about 3.0 μg 1 α ,24-dihydroxy vitamin D₄ per gram of lotion.

10 Example 21: Dermatological testing

Compositions containing 1 α ,24-dihydroxy vitamin D₄ are evaluated for therapeutic efficacy of the composition in the topical treatment of dermatitis (contact and ectopic). The composition evaluated is an ointment containing 10 μg of 1 α ,24-dihydroxy vitamin D₄ per gram of ointment in a petrolatum-almond oil base. The control composition is identical except that it does not contain the active agent 1 α ,24-dihydroxy vitamin D₄. The patients are treated in an out-patient clinic. They are instructed to use the preparation two times a day.

15 The ointment is as far as possible applied to a single lesion, or to an area of the disease. The ointment and its container are weighed before the treatment starts and returned with any unused contents for reweighing at the end of the treatment.

20 The area of the lesion treated is estimated and recorded, and the lesion is photographed as required, together with suitable "control" lesions. The latter are preferably lesions of similar size and stage of development, either in the vicinity of the treated lesion or symmetrically contralateral. Relevant details of the photographic procedure are recorded so as to be reproduced when the lesions are next

-27-

photographed (distance, aperture, angle, background, etc.). The ointment is applied twice daily and preferably left uncovered. The "control" lesions are left untreated, but if this is not possible, the treatment used on them is noted.

5 Evaluations of erythema, scaling, and thickness are conducted at weekly intervals by a physician, with the severity of the lesion rated from 0 to 3. The final evaluation is usually carried out at the end of four to six weeks of treatment. Those lesions treated with $1\alpha,24\text{-(OH)}_2\text{D}_4$ have lower scores than the control lesions. An insignificant incidence
10 of hypercalcemia is also observed.

Example 22: Epidermal cell differentiation and proliferation testing

Human keratinocytes are cultured according to known modifications of the system originally described by Rheinwald and Green (Cell, vol. 6, p. 331 (1975)). The $1\alpha,24$ -dihydroxy vitamin D_4 , dissolved
15 in ethanol, is added to cells to yield a variety of concentrations between 0.05 and 5 $\mu\text{g/ml}$ with the ethanol concentration not to exceed 0.5% v/v. Control cultures are supplemented with ethanol at a final concentration of 0.5% v/v.

Differentiation and proliferation of epidermal cells in culture is
20 examined by:

1. quantitation of cornified envelopes;
2. quantitation of cell density of cells attached to disks;
3. monitoring transglutaminase activity; or
4. monitoring DNA synthesis by incorporation of ^3H -thymidine.

25 Cultures incubated with $1\alpha,24$ -dihydroxy vitamin D_4 have more cornified envelopes, fewer attached cells, higher transglutaminase activity, and lower DNA synthesis than control cultures.

-28-

Example 23: Activity of $1\alpha,24-(OH)_2D_4$ in HL-60 cell differentiation assay

5 A dose-response study is conducted with $1\alpha,24-(OH)_2D_4$ in the HL-60 cell differentiation assay as described by DeLuca and Ostrom (DeLuca, H. F. and Ostrom, V. K., Prog. Clin. Biol. Res., vol. 259, pp. 41-55 (1988)). In this study, $1\alpha,25-(OH)_2D_3$ is used as a positive control and appropriate solvents are used as negative controls. The following variables are evaluated: nonspecific acid esterase activity, nitroblue tetrazolium (NBT) reduction, and thymidine incorporation. The results show that $1\alpha,24-(OH)_2D_4$ has potent activity in promoting differentiation of HL-60 promyelocytes to monocytes.

Example 24: Antiproliferative activity of $1\alpha,24-(OH)_2D_4$ in human cancer cell lines

15 Dose-response studies are conducted with $1\alpha,24-(OH)_2D_4$ in a battery of human cancer cell lines. These cell lines include, but are not limited to, the following: BCA-1 or ZR-75-1 (breast) and COL-1 (colon), as described by Shieh, H. L. et al. Chem. Biol. Interact., vol. 81, pp. 35-55 (1982). In this study, appropriate solvents are used as negative controls. The results show that $1\alpha,24-(OH)_2D_4$ has potent (and reversible) antiproliferative activity, as judged by inhibition of thymidine incorporation.

Example 25: Treatment of psoriasis

25 An oral dosage formulation containing $1\alpha,24$ -dihydroxyvitamin D_4 is evaluated in a double blind study for therapeutic efficacy of the formulation in the treatment of dermatitis (contact and ectopic). The formulation evaluated contains 1.0 to 10.0 μg of $1\alpha,24$ -dihydroxyvitamin D_4 . The control formulation is identical except that it does not contain the $1\alpha,24$ -dihydroxyvitamin D_4 . The patients are treated in an outpatient clinic and are divided into an experimental and

-29-

control population. They are instructed to take the medication once a day, in the morning before breakfast.

5 In each patient (experimental and control) an area of the skin containing a lesion is selected which is ordinarily covered by clothing and the patients are instructed not to expose the skin area selected for study to sunlight. The area of the lesion is estimated and recorded, and the lesion(s) is photographed. Relevant details of the photographic procedure are recorded so as to be reproduced when the lesions are next photographed (distance, aperture, angle, background, etc.).


10 Evaluations of erythema, scaling, and thickness are conducted at weekly intervals by a physician. The final evaluation is usually carried out at the end of four to six weeks of treatment. The results of the study show that daily oral administration of 1,24-dihydroxyvitamin D₃ significantly reduces the degree of erythema, scaling, and thickness
15 versus the control patients.

While the present invention has now been described and exemplified with some specificity, those skilled in the art will appreciate the various modifications, including variations, additions, and omissions, that may be made in what has been described. Accordingly, it is
20 intended that these modifications also be encompassed by the present invention and that the scope of the present invention be limited solely by the broadest interpretation that lawfully can be accorded the appended claims.

-30-

CLAIMS:

1. A method of inhibiting the hyperproliferative activity of human cancer cells, comprising treating the cancel cells with an effective amount of compound of formula (I):




(I)

- 5 wherein R_1 is either H or OH and R_2 is either H or OH and salts, hydrates and solvates thereof.
2. The method of claim 1 wherein the compound of formula (I) is 1 α ,24-dihydroxy vitamin D₄.
3. The method of claim 2 wherein the compound of formula (I) is 1 α ,24(R)-dihydroxy vitamin D₄, substantially free of its (S) form.
- 10 4. The method of claim 1 wherein said amount is about 1 μ g/dose to about 500 μ g/dose.


-31-

5. A method of treating a human to alleviate the hyperproliferative cellular activity of breast cancer and colon cancer, comprising administering to the human a therapeutically effective amount of compound of formula (I):



(I)

- 5 wherein R_1 is either H or OH and R_2 is either H or OH and salts, hydrates and solvates thereof.
6. The method of claim 5 wherein the compound of formula (I) is 1 α ,24-dihydroxy vitamin D₄.
7. The method of claim 6 wherein the compound of formula (I) is 1 α ,24(R)-dihydroxy vitamin D₄, substantially free of its (S) form.
8. The method of claim 5 wherein said therapeutic amount is about 1 μ g/dose to about 500 μ g/dose.
9. A pharmaceutical composition, comprising a compound of the formula (I):



(I)

wherein R_1 is either H or OH and R_2 is either H or OH in combination with a pharmaceutically acceptable vehicle.

10. The pharmaceutical composition of claim 9, wherein said composition is an oral composition and wherein the said compound of formula (I) is present at a concentration of about 1 $\mu\text{g/g}$ to about 100 $\mu\text{g/g}$ of composition.

11. The composition of claim 10, wherein the compound of formula (I) is 1 α ,24-dihydroxy vitamin D₄.

12. The composition of claim 11, wherein the compound of formula (I) is 1 α ,24(R)-dihydroxy vitamin D₄, substantially free of its (S) form.

13. The pharmaceutical composition of claim 9, wherein said composition is a topical composition and wherein the said compound of

-33-

formula (I) is present at a concentration of about 1 $\mu\text{g/g}$ to about 100 $\mu\text{g/g}$ of composition.

14. The composition of claim 13, wherein the compound of formula (I) is 1 α ,24-dihydroxy vitamin D₄.

5 15. The composition of claim 14, wherein the compound of formula (I) is 1 α ,24(R)-dihydroxy vitamin D₄, substantially free of its (S) form.

1/2




FIGURE 1

2/2




FIGURE 2

INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/US 96/09221

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/59

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BIOCHIM. BIOPHYS. ACTA, vol. 1091, no. 2, 1991, pages 188-192, XP000607142 F. SATO: "Biological activity of 1alpha,25-dihydroxyvitamin D derivatives - 24-epi-1alpha,25-dihydroxyvitamin D-2 and 1alpha,25-dihydroxyvitamin D-7"	1,9,10
Y	see the whole document	1-8
X	WO,A,92 05130 (LUNAR CORPORATION) 2 April 1992	9-15
Y	see page 6; claims	1-8
X	EP,A,0 562 497 (NISSHIN FLOUR MILLING CO., LTD.) 29 September 1993	9-15
Y	see page 7, line 43-47; claims	1-8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

13 November 1996

Date of mailing of the international search report

29. 11. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo rd,
Fax (+ 31-70) 340-3016

Authorized officer

Orviz Diaz, P

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/09221

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-8
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/09221

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9205130	02-04-92	AU-B- 650286	16-06-94
		AU-A- 8542291	15-04-92
		CA-A- 2069084	22-03-92
		CN-A,B 1061220	20-05-92
		EP-A- 0503035	16-09-92
		NZ-A- 239897	26-03-96
		US-A- 5488120	30-01-96
<hr/>			
EP-A-562497	29-09-93	JP-A- 5320127	03-12-93
<hr/>			